Alzheimer’s disease is notorious for robbing individuals of memory and cognitive function. Researchers have struggled for ...

There's still so much we don't know about Alzheimer's disease, but the link between poor sleep and worsening disease is one ...

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

which has just completed enrolment in a phase III trial of a tau-targeting drug in mild-to-moderate AD. Despite an R&D spend of around $15bn, a total of 20 beta amyloid protein-targeting drugs ...

A recent study revealed that an experimental blood test for Alzheimer’s disease not only can help in accurate diagnosis but ...

Amyloid-beta and tau accumulate long before noticeable symptoms of Alzheimer’s disease appear, sometimes decades earlier. Amyloid-beta plaques often develop first, starting in high-activity ...

A research team from the Institut de Neurociències of the Universitat Autònoma de Barcelona (INc-UAB) has discovered that the ...

The brain's immune cells removed plaques and helped restore a healthier environment in the brains of immunized patients. For over 30 years, scientists have focused on treating Alzheimer’s disease by ...

Encouraging interim results have supported Roche’s decision to move trontinemab into a pivotal Phase III programme.

The EMA has recommended refusing marketing authorization for donanemab, a monoclonal antibody against amyloid beta, in the ...